{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:08:50Z","timestamp":1791662930245,"version":"4.3.4"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Measurable residual disease (MRD)-directed interferon-a treatment (i.e. preemptive IFN-\u03b1 treatment) can eliminate the MRD in patients with acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Therefore, this study aimed to further assess its efficacy in a multicenter retrospective study in a real-world setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 247 patientswho received preemptive IFN-\u03b1 treatment were recruited from 4 hospitals in China. The protocols for MRD monitoring mainly based on quantitative polymerase chain reaction [qPCR] and multiparameter flow cytometry [MFC]. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median duration of IFN-\u03b1 treatment was 56 days (range, 1\u20131211 days). The cumulative incidences of all grades acute graft-versus-host disease (aGVHD), all grades chronic graft-versus-host disease (cGVHD), and severe cGVHD at 3 years after IFN-\u03b1 therapy were 2.0% (95% confidence interval [CI], 0.3\u20133.8%), 53.2% (95% CI, 46.8\u201359.7%), and 6.2% (95% CI, 3.1\u20139.2%), respectively. The cumulative incidence of achieving MRD negative state at 2 years after IFN-\u03b1 treatment was 78.2% (95% CI, 72.6\u201383.7%). The 3-year cumulative incidences of relapse and non-relapse mortality following IFN-\u03b1 therapy were 20.9% (95% CI, 15.5\u201326.3%) and 4.9% (95%CI, 2.0\u20137.7%), respectively. The probabilities of leukemia-free survival and overall survival at 3 years following IFN-\u03b1 therapy were 76.9% (95% CI, 71.5\u201382.7%) and 84.2% (95% CI, 78.7\u201390.1%), respectively. Multivariable analysis showed that MRD positive state by qPCR and MFC before IFN-\u03b1 treatment, high-risk disease risk index before allo-HSCT, and receiving identical sibling donor HSCT were associated with a higher risk of relapse and a poorer leukemia-free survival. Severe cGVHD was associated with an increased risk of non-relapse mortality. <\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Thus, real-world data suggest that preemptive IFN-\u03b1 is effective for treating patients with AML with MRD after allo-HSCT. <\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1091014","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T12:42:38Z","timestamp":1675341758000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Preemptive interferon-\u03b1 therapy could prevent relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: A real-world analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Shuang","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Zhong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ping","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Min","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Dong","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.scib.2022.09.004","article-title":"A vision for the future of allogeneic hematopoietic stem cell transplantation in the next decade","volume":"67","author":"Lv","year":"2022","journal-title":"Sci Bull"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2023.100373","article-title":"Development of allogeneic hematopoietic stem cell transplantation in 2022: Regenerating \u201cGroot\u201d to heal the world","volume":"4","author":"Lv","year":"2023","journal-title":"Innovation"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.306","article-title":"Causes of mortality after haploidentical hematopoietic stem cell transplantation and the comparison with HLA-identical sibling hematopoietic stem cell transplantation","volume":"51","author":"Yan","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eng.2020.12.005","article-title":"Disease risk comorbidity index for patients receiving haploidentical allogeneic hematopoietic transplantation","volume":"7","author":"Mo","year":"2021","journal-title":"Engineering"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.167","article-title":"Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. a review from the ALWP of the EBMT","volume":"51","author":"Tsirigotis","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12358","article-title":"Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation","volume":"162","author":"Campana","year":"2013","journal-title":"Br J Haematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14778","article-title":"Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post-transplantation minimal residual disease (MRD) monitoring and MRD-directed intervention","volume":"179","author":"Mo","year":"2017","journal-title":"Br J Haematol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.canlet.2018.08.030","article-title":"The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China","volume":"438","author":"Wang","year":"2018","journal-title":"Cancer Lett"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: A systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-380386","article-title":"Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation","volume":"119","author":"Yan","year":"2012","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/ejh.12591","article-title":"Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host disease control for minimal residual disease in acute leukemia\/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes","volume":"96","author":"Mo","year":"2016","journal-title":"Eur J Haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-2960-7","article-title":"Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia\/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation","volume":"96","author":"Mo","year":"2017","journal-title":"Ann Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.234","article-title":"Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial","volume":"26","author":"Platzbecker","year":"2012","journal-title":"Leukemia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1200\/JCO.20.01719","article-title":"Defining the role of donor lymphocyte infusion in high-risk hematologic malignancies","volume":"39","author":"Schmid","year":"2021","journal-title":"JAMA OncolJ Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.324","article-title":"Interferon-alpha in acute myeloid leukemia: an old drug revisited","volume":"25","author":"Anguille","year":"2011","journal-title":"Leukemia"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1948027","article-title":"Interferon-\u03b1 as maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia","volume":"62","author":"Jiang","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21346","article-title":"Successful cell-mediated cytokine-activated immunotherapy for relapsed acute myeloid leukemia after hematopoietic stem cell transplantation","volume":"84","author":"Gesundheit","year":"2009","journal-title":"Am J Hematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1948027","article-title":"Interferon alpha: the salvage therapy for patients with unsatisfactory response to minimal residual disease-directed modified donor lymphocyte infusion","volume":"127","author":"Mo","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.8817","article-title":"Controlled, randomized, open-label trial of risk-stratified corticosteroid prevention of acute graft-Versus-Host disease after haploidentical transplantation","volume":"34","author":"Chang","year":"2016","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000453","article-title":"Pegylated interferon-2alpha invokes graft-versus-leukemia effects in patients relapsing after allogeneic stem cell transplantation","volume":"3","author":"Henden","year":"2019","journal-title":"Blood Adv"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004908","article-title":"Type 1 interferon to prevent leukemia relapse after allogeneic transplantation","volume":"5","author":"Magenau","year":"2021","journal-title":"Blood Adv"},{"key":"B23","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s11684-019-0681-0","article-title":"Positive stool culture could predict the clinical outcomes of haploidentical hematopoietic stem cell transplantation","volume":"13","author":"Hu","year":"2019","journal-title":"Front Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.06.014","article-title":"Interferon-alpha: A potentially effective treatment for minimal residual disease in acute Leukemia\/Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation","volume":"21","author":"Mo","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B25","doi-asserted-by":"publisher","first-page":"20148","DOI":"10.1038\/s41598-020-77186-9","article-title":"Preemptive interferon-\u03b1 treatment could protect against relapse and improve long-term survival of ALL patients after allo-HSCT","volume":"10","author":"Liu","year":"2020","journal-title":"Sci Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0692","article-title":"Interferon-alpha is effective for treatment of minimal residual disease in patients with t(8;21) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: Results of a prospective registry study","volume":"23","author":"Mo","year":"2018","journal-title":"Oncologist"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.04.023","article-title":"IFN-\u03b1 is effective for treatment of minimal residual disease in patients with acute leukemia after allogeneic hematopoietic stem cell transplantation: Results of a registry study","volume":"23","author":"Mo","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.757002","article-title":"Preemptive interferon-\u03b1 therapy could protect against relapse and improve survival of acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation: Long-term results of two registry studies","volume":"13","author":"Shen","year":"2022","journal-title":"Front In Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.06.014","article-title":"Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning","volume":"18","author":"Weisdorf","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0686-3","article-title":"Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study","volume":"34","author":"Yu","year":"2020","journal-title":"Leukemia"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2021.11.002","article-title":"[Chinese consensus on minimal residual disease detection and interpretation of patients with acute myeloid leukemia (2021)]","volume":"42","year":"2021","journal-title":"Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2016.10.004","article-title":"[The consensus of allogeneic hematopoietic transplantation for hematological diseases in China(2016)\u2013 post- transplant leukemia relapse]","volume":"37","year":"2016","journal-title":"Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi"},{"key":"B33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13045-021-01159-2","article-title":"The consensus from the Chinese society of hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update","volume":"14","author":"Zhang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0691","article-title":"Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies","volume":"15","author":"Huang","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-627786","article-title":"Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.scib.2021.06.002","article-title":"Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial","volume":"66","author":"Wang","year":"2021","journal-title":"Sci Bull"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.scib.2018.08.008","article-title":"The role of collateral related donors in haploidentical hematopoietic stem cell transplantation","volume":"63","author":"Mo","year":"2018","journal-title":"Sci Bull"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25839","article-title":"Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute graft-versus-host disease: Updated experience from a large-scale study","volume":"95","author":"Liu","year":"2020","journal-title":"Am J Hematol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30249","article-title":"Comparison of outcomes after umbilical cord blood and unmanipulated haploidentical hematopoietic stem cell transplantation in children with high-risk acute lymphoblastic leukemia","volume":"139","author":"Mo","year":"2016","journal-title":"Int J Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-571570","article-title":"T-Cell-replete haploidentical HSCT with low-dose anti-t-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT","volume":"124","author":"Luo","year":"2014","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03742-7","article-title":"Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies","volume":"98","author":"Gao","year":"2019","journal-title":"Ann Hematol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40164-022-00278-x","article-title":"A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation","volume":"11","author":"Shen","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-418202","article-title":"A disease risk index for patients undergoing allogeneic stem cell transplantation","volume":"120","author":"Armand","year":"2012","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-Host disease: I. the 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-Host disease clinical data collection: A report from the mount Sinai acute GVHD international consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B46","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.223","article-title":"Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome","volume":"50","author":"Mo","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0366-6999.20122328","article-title":"Health related quality of life among patients with chronic graft-versus-host disease in China","volume":"126","author":"Mo","year":"2013","journal-title":"Chin Med J"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-319509","article-title":"Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the chronic GVHD consortium","volume":"117","author":"Pidala","year":"2011","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.58","article-title":"Chronic GVHD is associated with lower relapse risk irrespective of stem cell source among patients receiving transplantation from unrelated donors","volume":"47","author":"Signori","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.820285","article-title":"National institutes of health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen","volume":"55","author":"Saillard","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-623991","article-title":"Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide","volume":"125","author":"McCurdy","year":"2015","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.04.023","article-title":"Validation of the disease risk index for outcome of patients undergoing allogeneic hematopoietic stem cell transplantation after T cell depletion","volume":"20","author":"Beauverd","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B54","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/bjh.14962","article-title":"Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies","volume":"179","author":"Paviglianiti","year":"2017","journal-title":"Br J Haematol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"New Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1097\/BS9.0000000000000101","article-title":"The impact of venetoclax based regimens in the preemptive of measurable residual disease in acute myeloid leukemia","volume":"4","author":"Fang","year":"2022","journal-title":"Blood Sci"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16722","article-title":"Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia","volume":"192","author":"Tiong","year":"2021","journal-title":"Br J Haematol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1733-1","article-title":"Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity","volume":"92","author":"Zhao","year":"2013","journal-title":"Ann Hematol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-468348","article-title":"MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial","volume":"121","author":"Zhu","year":"2013","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1091014\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T12:42:48Z","timestamp":1675341768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1091014\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,2]]},"references-count":60,"alternative-id":["10.3389\/fimmu.2023.1091014"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1091014","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,2]]},"article-number":"1091014"}}